170 related articles for article (PubMed ID: 30249366)
1. Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers.
Conde-Carmona I; García-Medina S; Jiménez-Vargas JM; Martínez-Muñoz A; Lee SH
Clin Ther; 2018 Oct; 40(10):1729-1740. PubMed ID: 30249366
[TBL] [Abstract][Full Text] [Related]
2. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
Park SI; Lee H; Oh J; Lim KS; Jang IJ; Kim JA; Jung JH; Yu KS
Drug Des Devel Ther; 2015; 9():729-36. PubMed ID: 25678778
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
Shin D; Cho YM; Lee S; Lim KS; Kim JA; Ahn JY; Cho JY; Lee H; Jang IJ; Yu KS
Clin Drug Investig; 2014 Jun; 34(6):383-93. PubMed ID: 24627290
[TBL] [Abstract][Full Text] [Related]
4. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
Noh YH; Lim HS; Jin SJ; Kim MJ; Kim YH; Sung HR; Choi HY; Bae KS
Clin Ther; 2012 May; 34(5):1182-94. PubMed ID: 22534255
[TBL] [Abstract][Full Text] [Related]
5. Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers.
Choi HY; Noh YH; Kim YH; Kim MJ; Lee SH; Kim JA; Kim B; Lim HS; Bae KS
Int J Clin Pharmacol Ther; 2014 May; 52(5):381-91. PubMed ID: 24495314
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination
.
Lee SW; Park SI; Lee S; Chung JY; Yu KS
Int J Clin Pharmacol Ther; 2019 Feb; 57(2):117-124. PubMed ID: 30574864
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects.
Cho YS; Lee SH; Lim HS; Bae KS
J Korean Med Sci; 2018 Oct; 33(41):e258. PubMed ID: 30288156
[TBL] [Abstract][Full Text] [Related]
8. Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry.
Kim SH; Lee SH; Yim HJ
Arch Pharm Res; 2013 Oct; 36(10):1185-8. PubMed ID: 23771499
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers.
Choi HY; Kim YH; Kim MJ; Lee SH; Bang K; Han S; Lim HS; Bae KS
Drugs R D; 2014 Sep; 14(3):165-76. PubMed ID: 24962635
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects.
Choi HY; Lim HS; Kim YH; Jeon HS; Kim MJ; Lee SH; Jung JH; Lee YK; Kim HJ; Bae KS
Curr Med Res Opin; 2015 Feb; 31(2):229-41. PubMed ID: 25350224
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers: a randomized, open-label, 3-period, crossover, multiple-dose study.
Lee D; Roh H; Son H; Jang SB; Lee S; Nam SY; Park K
Clin Ther; 2014 Aug; 36(8):1171-81. PubMed ID: 24976448
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
Graefe-Mody EU; Padula S; Ring A; Withopf B; Dugi KA
Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study.
Yang E; Yoo H; Jang IJ; Yu KS; Lee S
Drug Des Devel Ther; 2021; 15():651-658. PubMed ID: 33628012
[TBL] [Abstract][Full Text] [Related]
14. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects.
Shin D; Kim TE; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Curr Med Res Opin; 2012 Jul; 28(7):1213-20. PubMed ID: 22697273
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers.
Kim SE; Yi S; Shin KH; Kim TE; Kim MJ; Kim YH; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Int J Clin Pharmacol Ther; 2012 Jan; 50(1):17-23. PubMed ID: 22192641
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 and Pharmacokinetic Drug-Drug Interaction Study of Metformin, Losartan, and Linagliptin Coadministered With DW1029M in Healthy Volunteers.
Moon SJ; Kim SY; Lim CH; Jang HB; Kim MG; Jeon JY
Clin Pharmacol Drug Dev; 2017 Jul; 6(4):408-419. PubMed ID: 27739231
[TBL] [Abstract][Full Text] [Related]
18. Safety and pharmacokinetic interaction between fotagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin in healthy subjects.
Ding Y; Zhang H; Li C; Zheng W; Wang M; Li Y; Sun H; Wu M
Expert Opin Drug Metab Toxicol; 2021 Jun; 17(6):725-731. PubMed ID: 33899649
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic Interaction Between Amlodipine and Lobeglitazone, a Novel Peroxisome Proliferator-activated Receptor-γ Agonist, in Healthy Subjects.
Kim CO; Sil Oh E; Kim C; Park MS
Clin Ther; 2015 Sep; 37(9):1999-2006.e1. PubMed ID: 26163202
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).
Lim S; Han KA; Yu J; Chamnan P; Kim ES; Yoon KH; Kwon S; Moon MK; Lee KW; Kim DJ; Kim M; Wongtanate M; Kim EY; Kim SH; Lee MK;
Diabetes Obes Metab; 2017 Jan; 19(1):87-97. PubMed ID: 27619558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
